Xue, Kanmin, Jolly, Jasleen K., Barnard, Alun R., Rudenko, Anna, Salvetti, Anna, Patricio, Maria, Edwards, Thomas, Groppe, Markus, Orlans, Harry, Tolmachova, Tanya, Black, Graeme C., Webster, Andrew R., Lotery, Andrew, Holder, Graham E., Downes, Susan, Seabra, Miguel C. and MacLaren, Robert E. (2018) Beneficial effects on vision in patients undergoing retinal gene therapy for choroideremia. Nature Medicine, 24, 1507-1512. (doi:10.1038/s41591-018-0185-5).
Abstract
Retinal gene therapy is increasingly recognised as a novel molecular intervention that has huge potential in treating common causes of blindness, the majority of which have a genetic aetiology. Choroideremia is a chronic X-linked retinal degeneration that was first described in 1872. It leads to progressive blindness due to deficiency of Rab-escort protein 1 (REP1). We designed an adeno-associated viral vector to express REP1 and assessed it in a gene therapy clinical trial by subretinal injection in 14 patients with choroideremia. The primary endpoint was vision change in treated eyes two years after surgery compared to unoperated fellow eyes. Despite complications in two patients, visual acuity improved in the 14 treated eyes over controls (median 4.5 letter gain, vs 1.5 letter loss, p=0.04), with six treated eyes gaining more than one line of vision (>5 letters). The results suggest that retinal gene therapy can sustain and improve visual acuity in a cohort of predominantly late stage choroideremia patients in whom rapid visual acuity loss would ordinarily be predicted.
More information
Identifiers
Catalogue record
Export record
Altmetrics
Contributors
Download statistics
Downloads from ePrints over the past year. Other digital versions may also be available to download e.g. from the publisher's website.